Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and Cetuximab in Recurrent or Metastatic HNSCC
NCT03667482Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2018
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cabozantinib in head and neck squamous cell carcinoma (HNSCC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Sep 2018; status: completed.
02
Drugs
cabozantinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03667482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03667482.